oa South African Medical Journal - Suggested method of rendering butazolidin less harmful
The theories applying to the use of a catalyst ferrous iron, in activating the redux potential of vitamin C have been discussed. Implementation of the redux potential is claimed to neutralize the progress of agranulocytosis and allied blood disorders such as thrombocytopoenia, capillary fragility, etc. Two cases being treated for rheumatoid arthritis with butazolidin and vitamin C developed evidence of agranulocytosis. This complication of the arthritic therapy was overcome by the addition of a catalyst ferrous iron to the vitamin and butazolidin. No relapse has occurred during treatment persevered with for some weeks. Further research and trial of the method is advocated.
Article metrics loading...